Dr. Reddy’s Q2 Review: Systematix Maintains ‘Hold’ Post Inline Results

Dr. Reddy’s Laboratories Ltd.’s Q2 FY26 earnings were inline with estimates. Revenue and PAT grew 10% and 6% YoY respectively. Systematix maintains ‘Hold’ post inline results, citing strong performance in ex-US markets.

Q2 FY26 Earnings Review

Dr. Reddy’s Q2 FY26 revenue, Rs 88,051 million, was up 10% YoY and 3% flat QoQ. Ebitda, at Rs 23,511 million, rose 3% YoY and QoQ. Ebitda margin stood at 26.7% and was down by 175 YoY and flat on a QoQ basis.

The decline in Ebitda margin was primarily due to lower gross margins, which were down 500 bps YoY. This was attributed to price erosion in North America and lower contribution from PLI incentive.

Strong Performance in Ex-US Markets

Despite the challenges in North America, Dr. Reddy’s performed well in ex-US markets. The company’s revenue from emerging markets, including India, grew significantly, driven by strong demand for its products.

Dr. Reddy’s has a strong presence in the Indian pharmaceutical market, with a wide range of products across various therapeutic segments. The company’s focus on Research and Development has helped it to stay ahead of the competition and launch new products in the market.

Systematix Maintains ‘Hold’ Rating

Systematix has maintained its ‘Hold’ rating on Dr. Reddy’s, citing the company’s strong performance in ex-US markets and its ability to navigate the challenges in North America.

The brokerage firm has noted that Dr. Reddy’s has a strong product pipeline, with several new launches expected in the coming quarters. This is expected to drive growth for the company and help it to maintain its market share.

Indian Pharmaceutical Sector Outlook

The Indian pharmaceutical sector has been performing well, driven by strong demand for generic drugs and a favorable regulatory environment.

The sector has seen significant investments in Research and Development, with several companies focusing on developing new products and expanding their product portfolios.

The government’s initiatives to promote the sector, including the Pharmaceutical Innovation Policy, are also expected to drive growth for the sector.

Investment Strategy

Investors looking to invest in the Indian pharmaceutical sector can consider companies with a strong product pipeline and a presence in emerging markets.

Dr. Reddy’s is one of the largest pharmaceutical companies in India, with a strong presence in the domestic market and a significant presence in emerging markets.

Investors can also consider other pharmaceutical companies, such as Sun Pharmaceutical Industries and Cipla, which have a strong presence in the Indian market and a significant presence in emerging markets.

Conclusion

Dr. Reddy’s Q2 FY26 earnings were inline with estimates, with revenue and PAT growing 10% and 6% YoY respectively. Systematix has maintained its ‘Hold’ rating on the company, citing its strong performance in ex-US markets and its ability to navigate the challenges in North America.

Investors looking to invest in the Indian pharmaceutical sector can consider companies with a strong product pipeline and a presence in emerging markets. Dr. Reddy’s is one of the largest pharmaceutical companies in India, with a strong presence in the domestic market and a significant presence in emerging markets.